I could be wrong but we are being assessed against the current standard of care. That is currently other TAVR devices. So I assume we would publish our results against the thousands of existing published results for existing on market devices. (these well documented results make up the current standard of care.)
I don’t think we actually implant other companies devices in this trial.
Not advice and DYOR.
Ann: Annual Report to shareholders, page-9
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.01 |
Change
-0.040(0.21%) |
Mkt cap ! $365.4M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.01 | $18.77 | $39.53K | 2.091K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.01 | 3 | 1 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |